Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

Phase 1TerminatedNCT05366439

Atea Pharmaceuticals, Inc.5 enrolled

Overview

This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

A Phase 1, double-blind, randomized, placebo-controlled study to assess the antiviral activity and safety of AT-752 in a Dengue Human Challenge Model

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Dengue

Interventions

AT-752DRUG

Parallel Assignment

Placebo ComparatorDRUG

Parallel Assignment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Must agree to use protocol-specified methods of contraception * Negative pregnancy test * Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: * Pregnant or breastfeeding * Abuse of drugs * Other clinically significant medical conditions

Locations (1)

Atea Study Site

Syracuse, New York, United States

Outcomes

Primary Outcomes

Mean quantitative RNAemia (peak and duration and area under the plasma concentration versus time curve [AUC])

Time frame: Day 2 until 28 days post virus inoculation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.